TRAW
Traws Pharma, Inc.
$1.28
+0.79%
$19.4M
No data for this timeframe.
Vol
Market Cap$19.4M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders12 funds
Inst. Value$1.6M
Inst. Activity1 buys / 0 sells
Insider Activity4B / 0S
Insider Net $$998.2K
Reddit Sentiment50° Neutral
SEC Reports12
Press Releases2
Recent Activity
Jun 12, 2026
SEC
Traws Pharma disclosed that its planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) has been d
8-K — Impact 7/10
Jun 12, 2026
other
Traws Pharma Provides Regulatory Update on Influenza Program
<p align="justify">NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRA
May 29, 2026
SEC
Traws Pharma filed DEFA14A additional definitive proxy soliciting materials for its 2026 Annual Meeting scheduled for Ju
DEFA14A — Impact 3/10
May 27, 2026
SEC
Traws Pharma announced a new broad-spectrum antiviral program targeting Hantavirus and Ebola outbreaks, utilizing a prop
8-K — Impact 4/10
Apr 16, 2026
Insider
ORBIMED ADVISORS LLC bought 1,793,187 shares
10%+ Owner
Apr 16, 2026
Insider
ORBIMED ADVISORS LLC bought 597,729 shares
10%+ Owner @ $1.67 ($998.2K)
Apr 16, 2026
Insider
ORBIMED ADVISORS LLC bought 597,729 shares
10%+ Owner
Inst.
FMR LLC — DOUBLED
23 shares ($42.00)
Price Targets
$5.50
+329.7% upside
Strong Buy
Current $1.28
Low $3.00
Median $5.50
High $8.00
2 analysts
$3.00
$8.00
Analyst Ratings
3Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 20, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.20 ▼ -33.3% | $-1.20 — $-1.20 | 1 | |
| Next Q | $-0.63 ▲ +49.6% | $-0.63 — $-0.63 | 1 | |
| Current FY | $-3.13 ▲ +27.5% | $-3.13 — $-3.13 | -33% YoY | 1 |
| Next FY | $-4.03 ▲ +14.4% | $-4.03 — $-4.03 | -29% YoY | 1 |
Latest Reports
BEARISH
8-K
7/10
Traws Pharma disclosed that its planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) has been d
Jun 12, 2026
NEUTRAL
DEFA14A
3/10
Traws Pharma filed DEFA14A additional definitive proxy soliciting materials for its 2026 Annual Meeting scheduled for Ju
May 29, 2026
NEUTRAL
Press
4/10
Traws Pharma announced plans to develop clinical candidates for hantavirus treatment following a recent outbreak linked
May 8, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| ADAGE CAPITAL PARTNERS GP, | $1.3M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $101.0K | — |
| VANGUARD FIDUCIARY TRUST CO | $58.2K | — |
| STATE STREET CORP | $47.2K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 16, 2026 | ORBIMED ADVISORS | BUY | $0.00 |
| Apr 16, 2026 | ORBIMED ADVISORS | BUY | $998.2K |
| Apr 16, 2026 | ORBIMED ADVISORS | BUY | $0.00 |
| Apr 16, 2026 | ORBIMED ADVISORS | BUY | $0.00 |
| Mar 8, 2026 | Shoemaker Mary | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
12 institutional holders with $1.6M total value (876,023 shares) as of 2026-Q1. Top holders: ROYAL, ADAGE, VANGUARD. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 6 | $0.00 | 0.0% | — |
| 2 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 730,000 | $1.3M | 83.3% | DOUBLED +121.2% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 55,193 | $101.0K | 6.3% | — |
| 4 | VANGUARD FIDUCIARY TRUST CO | 31,804 | $58.2K | 3.6% | — |
| 5 | STATE STREET CORP | 25,802 | $47.2K | 2.9% | — |
| 6 | TWO SIGMA INVESTMENTS, LP | 19,244 | $35.2K | 2.2% | ADD +37.1% |
| 7 | BlackRock, Inc. | 9,956 | $18.2K | 1.1% | — |
| 8 | MORGAN STANLEY | 3,729 | $6.8K | 0.4% | NEAR_EXIT -95.4% |
| 9 | Vanguard Global Advisers, LLC | 262 | $479.00 | 0.0% | — |
| 10 | FMR LLC | 23 | $42.00 | 0.0% | DOUBLED +1050.0% |
| 11 | JONES FINANCIAL COMPANIES LLLP | 2 | $4.00 | 0.0% | — |
| 12 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 2 | $4.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | DOUBLED | 2 | 23 | +1050.0% | $42.00 | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 330,000 | 730,000 | +121.2% | $824.9K | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 13,173 | 87,259 | +562.4% | $161.4K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 16,063 | 22,018 | +37.1% | $40.7K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 3,006 | 6 | -99.8% | $11.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 14,323 | 3,006 | -79.0% | $4.4K | 2025-Q2 |
| Alyeska Investment Group, L.P. | TRIM | 116,714 | 52,630 | -54.9% | $121.0K | 2025-Q1 |
| UBS Group AG | DOUBLED | 791 | 14,323 | +1710.7% | $32.9K | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 15,725 | 725 | -95.4% | $1.7K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 729 | 15,725 | +2057.1% | $139.6K | 2024-Q4 |
| VANGUARD GROUP INC | TRIM | 26,722 | 13,141 | -50.8% | $116.7K | 2024-Q4 |
| GROUP ONE TRADING LLC | DOUBLED | 64 | 1,164 | +1718.8% | $10.3K | 2024-Q4 |
| UBS Group AG | ADD | 630 | 791 | +25.6% | $7.0K | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 2,138 | 76 | -96.4% | $675.00 | 2024-Q4 |
11 unique insiders with 17 transactions. Net insider value: $998.2K ($998.2K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 16, 2026 | ORBIMED ADVISORS LLC | 10%+ Owner | BUY | 1,793,187 | — | — |
| Apr 16, 2026 | ORBIMED ADVISORS LLC | 10%+ Owner | BUY | 597,729 | $1.67 | $998.2K |
| Apr 16, 2026 | ORBIMED ADVISORS LLC | 10%+ Owner | BUY | 597,729 | — | — |
| Apr 16, 2026 | ORBIMED ADVISORS LLC | 10%+ Owner | BUY | 597,729 | — | — |
| Mar 8, 2026 | Shoemaker Mary Teresa | Director | AWARD | 33,435 | — | — |
| Mar 8, 2026 | Parker Charles Nolan | Chief Financial Officer | AWARD | 104,544 | — | — |
| Mar 8, 2026 | Leaman John Harold | Director | AWARD | 33,435 | — | — |
| Mar 8, 2026 | STOVER JACK E | Director | AWARD | 33,435 | — | — |
| Mar 8, 2026 | Clarke Trafford | Director | AWARD | 33,435 | — | — |
| Mar 8, 2026 | CAUTREELS WERNER | Director | AWARD | 31,258 | — | — |
| Mar 8, 2026 | Dukes Iain D. | Chief Executive Officer | AWARD | 231,336 | — | — |
| Mar 8, 2026 | Pauza Charles David | Chief Science Officer Virology | AWARD | 118,367 | — | — |
| Mar 8, 2026 | Savchuk Nikolay | Chief Operating Officer | AWARD | 96,899 | — | — |
| Mar 8, 2026 | Redfield Robert | Chief Medical Officer | AWARD | 108,854 | — | — |
| Dec 12, 2025 | Parker Charles Nolan | Chief Financial Officer | AWARD | 15,393 | — | — |
| Dec 12, 2025 | Parker Charles Nolan | Chief Financial Officer | AWARD | 61,571 | — | — |
| Oct 12, 2025 | Parker Charles Nolan | Chief Financial Officer | AWARD | 32,406 | — | — |
12 SEC filing reports analyzed. Sentiment: 1 bullish, 6 bearish, 2 mixed, 3 neutral. Avg impact: 6.0/10.
BEARISH
8-K
7/10
Traws Pharma disclosed that its planned Phase 2a human influenza challenge study for tivoxavir marbo
Jun 12, 2026
NEUTRAL
DEFA14A
3/10
Traws Pharma filed DEFA14A additional definitive proxy soliciting materials for its 2026 Annual Meet
May 29, 2026
NEUTRAL
8-K
4/10
Traws Pharma announced a new broad-spectrum antiviral program targeting Hantavirus and Ebola outbrea
May 27, 2026
NEUTRAL
8-K
3/10
Traws Pharma filed an 8-K to update its at-the-market (ATM) offering program, supplementing its exis
May 26, 2026
BEARISH
424B5
7/10
Traws Pharma filed a 424B5 prospectus supplement to increase the ATM offering capacity by up to $3.1
May 22, 2026
BEARISH
EFFECT
7/10
Traws Pharma's S-3 shelf registration (File No. 333-295727) became effective on May 15, 2026, enabli
May 18, 2026
BEARISH
8-K
7/10
Traws Pharma reported Q1 2026 results with zero revenue and a net loss of $7.1M ($-0.53/share), a sh
May 15, 2026
MIXED
PRESS-RELEASE
5/10
Traws Pharma reported Q1 2026 results with a net loss of $7.1M (-$0.53 EPS, beating the -$0.56 conse
May 15, 2026
BEARISH
S-3
8/10
Traws Pharma filed an S-3 registration statement to register 35,897,514 shares for resale by selling
May 8, 2026
MIXED
8-K
7/10
Traws Pharma reported a net income of $9.2 million for FY2025, a significant improvement from a $166
Apr 15, 2026
BULLISH
PRESS-RELEASE
8/10
Traws Pharma reported a dramatic year-over-year swing from a $166.5M loss in 2024 to a $9.2M net inc
Apr 15, 2026
BEARISH
8-K
6/10
Traws Pharma raised $10 million through a private placement of common stock and multiple tranches of
Apr 15, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 3 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.50 mean target
+329.7% upside
Strong Buy (3.00)
$3.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $1.28 |
| Target Low | $3.00 |
| Target Mean | $5.50 |
| Target Median | $5.50 |
| Target High | $8.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.20 | $-1.20 | $-1.20 | — | -33.3% | 1↑ 0↓ | $0.0B | — | 1 |
| Next Q 2026-09-30 |
$-0.63 | $-0.63 | $-0.63 | — | +49.6% | 1↑ 0↓ | $0.0B | — | 1 |
| Current FY 2026-12-31 |
$-3.13 | $-3.13 | $-3.13 | -33.1% | +27.5% | 1↑ 0↓ | $0.0B | -100.0% | 1 |
| Next FY 2027-12-31 |
$-4.03 | $-4.03 | $-4.03 | -28.7% | +14.4% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.200 | |
| 7d ago | $-1.010 | -0.190 |
| 30d ago | $-0.900 | -0.300 |
| 60d ago | $-0.900 | -0.300 |
| 90d ago | $-0.900 | -0.300 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 20, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
4 mentions
0 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 17, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 17, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 12, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 12, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 12, 2026
other
Traws Pharma Provides Regulatory Update on Influenza Program
<p align="justify">NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutica
May 27, 2026
other
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
<p align="center"><em>Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa</em></p>
May 20, 2026
short_volume
Short Volume: TRAW — 72.2% short (0.4M / 0.5M)
Short: 366,124 | Exempt: 136,166 | TRF Vol: 507,392 | Short Ratio: 72.2% | Off-exchange volume (dark pool + OTC)
May 15, 2026
earnings
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
<p align="center"><em>Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support op
May 15, 2026
short_volume
Short Volume: TRAW — 61.0% short (0.5M / 0.9M)
Short: 528,669 | Exempt: 65,884 | TRF Vol: 866,603 | Short Ratio: 61.0% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
TRAW Q1 2026 Earnings Scheduled — 2026-05-13
May 13, 2026
short_volume
Short Volume: TRAW — 61.3% short (0.4M / 0.6M)
Short: 372,993 | Exempt: 37,556 | TRF Vol: 608,297 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: TRAW — 57.2% short (0.8M / 1.4M)
Short: 775,837 | Exempt: 78,173 | TRF Vol: 1,355,416 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: TRAW — 56.6% short (9.8M / 17.3M)
Short: 9,772,262 | Exempt: 89,261 | TRF Vol: 17,254,430 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_interest
FTD: TRAW — 741,854 shares ($1.6M) failed to deliver
Settlement: 20260511, Price: $2.18, FTD Value: $1,617,241.72, TRAWS PHARMA, INC. COM NEW PAR
May 8, 2026
fda
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
<p align="justify">NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a cl
May 8, 2026
short_volume
Short Volume: TRAW — 58.4% short (17.3M / 29.6M)
Short: 17,289,288 | Exempt: 247,146 | TRF Vol: 29,590,566 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
earnings
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
<p align="center"><em>Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad p
Apr 15, 2026
offering
Traws Pharma Announces Up to $60 Million Private Placement Financing
<p align="justify">NEWTOWN, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, “Traws Pharma”, “Traws” or “the Company”), a c
Apr 15, 2026
earnings_calendar
TRAW Q4 2025 Earnings After Market Close — 2026-04-15